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Abbreviations and Acronyms 
TRA = transradial access 
TFA = transfemoral access 
PCI = percutaneous coronary intervention 
MACE = major adverse cardiovascular events 
ACS = acute coronary syndrome 
NHS = National Health Service 
OTV = the yearly Operator Total Volume  
ORV = the yearly Operator Radial Volume 
ORP = the yearly Operator Radial Proportion (ORP=ORV/OTV)  
CTV = the yearly Centre Total Volume  
CRV = the yearly Centre Radial Volume 
CRP = the yearly Centre Radial Proportion (CRP=CRV/CTV)  
STEMI = ST elevated myocardial infarction 
NSTEMI = non-ST elevated myocardial infarction 
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What is Known: 
• The transradial access site has grown to be the default access site for PCI in Europe 
and it is rapidly growing in adoption within the United States. 
• Procedural volume for PCI at both the operator and institutional level has been linked 
both to improved mortality and procedural outcomes.  
• Procedural volume and expertise may equally be important for outcomes associated 
with access site. 
What the Study Adds: 
• This largest study to date found significant variation in access site practice at both the 
individual operator and center level according to volume of procedures undertaken, 
with TRA used more commonly as operator/center volume increase.  
• We demonstrate that the lower mortality associated with TRA adoption relates to the 
proportion of procedures undertaken through the radial approach, and also the total 
volume of procedures, with operators undertaking the greatest proportion of their 
procedures radially having the largest relative reduction in mortality risk. We observe 
that the reduced mortality associated with TRA does not relate to either total volume 
or radial volume at the center level once other covariates of patient clinical 
demographics and operator experience are adjusted for. 
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Abstract 
Background: Transradial access (TRA) is associated with reduced access site related 
bleeding complications and mortality post percutaneous coronary intervention (PCI).  The 
objective of this study is to examine the relationship between access site practice and clinical 
outcomes and how this may be influenced by operator and center experience/expertise. 
Methods and Results: The influence of operator and center experience/expertise was studied 
on 30-day mortality, in-hospital MACE (a composite of in-hospital mortality and in-hospital 
myocardial infarction and target vessel revascularization) and in-hospital major bleeding 
based on access site adopted (radial vs femoral). Operator/center experience/expertise were 
defined by both total volume and TRA proportion. A total of 164,395 procedures between 
2012 and 2013 in the NHS in England and Wales were analyzed. After case-mix adjustment, 
TRA was associated with an average odds reduction of 39% for 30-day mortality compared 
with transfemoral access (TFA) (OR = 0.61, 95% CI 0.55-0.68, p<0.001). The magnitude of 
this risk reduction was modified by increases in total procedural volume and radial proportion 
at the operator level (OR reduction of 11% per 100 extra procedures, 95% CI 3-19%; OR 
reduction of 8%6% per 10%-point increase in radial proportion, 95% CI 3-12%1-11%) with 
no significant impact of operator radial volume, center total volume, center radial volume and 
center radial proportion. 
Conclusions: The lower mortality associated with TRA adoption relates to both the total 
procedural volume and the proportion of procedures undertaken radially by operator, with 
operators undertaking the greatest proportion of their procedures radially having the largest 
relative reduction in mortality risk.  
 
Keywords: Operator volume, Center volume, Access site, Mortality 
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Introduction 
 
 The transradial (TRA) access site has been adopted as the preferred access site for 
percutaneous coronary intervention (PCI) in the United Kingdom and many countries across 
Europe.1-3 TRA is associated with decreased mortality rates in specific patient groups,4-8 at 
least in part through a reduction in major bleeding complications.9 Radial access is 
technically more challenging than femoral and has a longer learning curve requiring higher 
volumes to achieve and maintain proficiency.10,11 
 Procedural volume for percutaneous coronary intervention (PCI) at both the operator 
and institutional level has been linked both to improved mortality and procedural 
outcomes.12,13 Similarly, procedural volume and expertise may equally be important for 
outcomes associated with TRA utilization. Data derived from the RIVAL (RadIal Vs. 
femorAL) trial, that randomized 7,021 patients with acute coronary syndromes (ACS) to 
radial versus femoral access for PCI, suggests that procedural radial volumes may impact on 
PCI outcomes associated with the TRA utilization.14,15 Whilst in the subgroup of high-
volume radial centers the primary outcome was reduced by adoption of TRA, this was not 
observed in intermediate- or low-volume radial centers and furthermore there was no 
significant interaction by individual operator radial volume.14 Other studies reporting 
outcomes in the Veteran Affairs (VA) healthcare system have suggested that blood 
transfusions were significantly less frequent in high volume radial centers (defined as ≥50 
TRA procedures per year) compared to procedures undertaken through the transfemoral 
access (TFA), although this relationship was not observed in low volume radial centers, 
although TRA adoption in even the highest volume centers was only 35% in the setting of 
national TRA rates of only 9%. 
  
 Whilst previous work has studied the relationship between center and operator radial 
volume and its relationship between access site related outcomes,15,16 these data have some 
limitations. Firstly, some data are derived in the setting of randomized controlled trials, 
therefore in highly selected patient cohorts in whom PCIs were undertaken in experienced 
centers with experienced operators.14,15 Second, data are derived from centers in North 
America where procedural center volumes of ≥50 TRA procedures per year (defined as high 
volume radial centers) would be considered low volume in countries where TRA represents 
the default access site (such as the UK). Whilst “center” and “operator” TRA volumes may 
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be considered markers of TRA expertise, this will clearly be dependent on total PCI center 
and operator volumes, hence high volume centers and operators who only do a small 
proportion of their cases through the TRA route would numerically still be considered as 
experienced “high volume” radial centers/operators in previous analyses. The proportion of 
cases undertaken through the TRA, is an important marker of radial experience and expertise 
since high proportion TRA operators will undertake PCI cases through the TRA in the most 
challenging cases but this has not been considered or adjusted for in previous analyses. Often 
such patients are at the highest risk of bleeding complications and derive most benefit from 
the TRA approach.5 
 We have therefore studied the relationship between access site practice and clinical 
outcomes in the United Kingdom and how this relationship may be associated with operator 
and center experience/expertise, as defined by both the volume and proportion of cases 
undertaken through the TRA. Furthermore, we also study the clinical characteristics and 
procedural demographics of patients in whom TRA is the access site adopted for PCI by 
operators/centers with differing degrees of TRA experience/practice. 
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Methods 
 
The British Cardiovascular Intervention Society Database 
 The British Cardiovascular Intervention Society (BCIS) collects data on all PCI 
procedures in the UK17-19 and data collection is coordinated by the National Institute of 
Cardiovascular Outcomes Research (http://www.ucl.ac.uk/nicor/) via the Central Cardiac 
Audit Database. In 2011, this dataset collected information on 99.4% of all PCI procedures 
performed in National Health Service Hospitals in England and Wales. The BCIS-NICOR 
database comprises 113 variables, including clinical variables, procedural parameters and 
patient outcomes. Mortality tracking is undertaken by theMedical Research Information 
Service using patients’ National Health Service (NHS) numbers that provide a unique 
identifier for any person registered with the NHS in England andWales. 
 
Study definitions 
The data presented relate to allreported PCI procedures undertaken in patients in 
England and Wales between January 1, 2012 and December 31, 2013.PCI procedures 
performed via the left or right femoral artery or the left or right radial artery were included in 
the TFA and TRA cohorts, respectively. Procedures involving a switch from one access site 
to another, or where access site was unknown, were excluded. The outcomes examined were 
in-hospital major adverse cardiovascular events (MACE) (a composite of in-hospital 
mortality and in-hospital myocardial infarction or re-infarction and target vessel 
revascularization), in-hospital major bleeding (defined as gastrointestinal bleed, intra-cerebral 
bleed, retroperitoneal hematoma, blood or platelet transfusion, or an arterial access site 
complication requiring surgery) and 30-day mortality. 
 
Statistical Methods 
Descriptive 
 Three measures of “operator experience” were considered: the yearly Operator Total 
Volume (OTV), the yearly Operator Radial Volume (ORV), and the yearly Operator Radial 
Proportion (ORP=ORV/OTV). Analogousannualized measures of “center experience”, CTV, 
CRV, CRP, were also considered. TRA proportion was plotted against volume for operator 
and for center to examine their relationships. Individual operator identity was derived from a 
unique General Medical Council (GMC) number derived from the BCIS dataset available 
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from 2012 that each medical practitioner licensed to practice medicine in the UK is allocated 
when first registered with the GMC. It is a statuary requirement to be registered with the 
GMC to practice medicine in the UK. 
 In order to examine the relationship between case mix and experience, cases were 
divided into four groups according to each of these three measures; quartiles defined the 
group boundaries for the OTV, ORV, CTV and CRV and boundaries for ORP and CRP were 
at values of 25%, 50% and 75%. Important aspects of case mix (e.g. variables such as age, 
shock) were then tabulated per group against access site. These tables were presented with 
column percentages for categorical variables, which can be interpreted as an indication of 
how case mix varies by access site. To test for association between demographic and clinical 
variables and access site choice within strata, t-tests were used for continuous variables and 
Chi-squared-tests for categorical variables. Logistic regression was used to determine 
whether access site choice differed between experience groups; Access site (TRA only or 
TFA only) was the binary outcome, and we report the p-value from the test of inclusion of an 
interaction term between the demographic/clinical variable and experience group.  
 
Modeling 
 Logistic regression was used for each outcome (30-day mortality, major bleeding, and 
MACE). The exposures of interest were access site, operator/center experience, and the 
interactions between access site and experience.  Models were adjusted for demographic and 
clinical confounders. Two strategies were employed to deal with intra-patient dependencies, 
with analyzes from each strategy performed in parallel; the first strategy assumed all 
procedures were independent so that no design modifications were necessary, while the 
second permitted only the first procedure for each patient during the study period to enter the 
analysis cohort. After removing observations where the exposure was missing, multiple 
imputation was implemented. Ten datasets were imputed in total and the models developed 
on each of these were pooled using Rubin’s rules.20 The same ten datasets were used for each 
outcome analysis so that each analysis was drawn from the same imputation model and to 
eliminate the need to reimpute for each outcome. To allow for this, each of the three outcome 
variables were included in the chained imputation equations but crucially, at the model 
development and analysis stage observations were removed if the outcome of interest was 
originally missing, i.e., a ‘multiple imputation then deletion’ strategy.21 
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 Clinical and demographic confounders were chosen a priori based on availability and 
clinical relevance: age, gender, year of operation, indication for treatment (Stable angina, 
Unstable angina/NSTEMI, STEMI), presence of diabetes, renal function, coronary artery 
bypass graft, shock, intra-aortic balloon pump, cardiopulmonary support, inotropic support, 
ventilation, stent type, smoking status, high cholesterol, previous myocardial infarction, left 
ventricular ejection fraction (LVEF), and use of glycoprotein IIb/IIIa drugs were all adjusted 
for. First-order interactions were considered. 
 Models were considered which combined all three measures of experience (along 
with interactions with access site). Models adjusting for a single measure of experience were 
also examined, with and then without adjusting for other covariates. Non-linear effects were 
considered for the measures of experience via restricted cubic splines with four knots1
 Odds ratios comparing odds of adverse outcomes for radial access with odds for 
femoral access site were plotted against each measure of experience, along with 95% 
confidence intervals, for the models considered.  
A secondary analysis was performed to investigate if the experience-
outcomerelationships observed in the primary analysis were still present when restricting to 
non-cardiogenic procedures. 
 
Software 
 All data preparation and analyses were performed using R version 3.2.0.23The mice 
package24 was used for multiple imputation.  
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Results 
Study cohort 
 A total of 164,395 procedures were performed in patients in England and Wales 
between January 1, 2012 and December 31 2013 and the influence of operator and center 
total volume, radial volume and radial proportions on outcomes was studied. Figure 1 
illustrates a flowchart that tracks the process by which observations are removed from the 
analysis cohorts and the stages at which experience measures are calculated. Experience 
measure and the descriptive analysis was performed in 149,165 procedures. Amongst these, 
operators are typically high proportion radial or high proportion femoral with few operators 
performing around 50% of each, with high volume centers more likely to be high-proportion 
radial centers (Figure 2). During the study period radial proportion increased steadily from 
60.4% in January-March 2012 to 70.1% in October-December 2013 as illustrated in Figure 3. 
In total 145,250 procedures were used in the primary mortality analysis.  Restricting the 
analysis cohort to patients undergoing their first procedure during the study period removed 
13,055 (9%) procedures from full cohort, with results from this cohort versus the full cohort 
practically equivalent. We therefore only present results from the analysis of the full cohort. 
Operator and center volumes and access site related outcomes 
 The influence of operator and center volumes on access site related outcomes were 
studied. Table 1 illustrates clinical and procedural demographics for the TRA and TFA 
groups by operator annual procedural volumes. Table 1 shows that as operator volume 
increased across groups, TRA increased from 54.3% in lowest OTV group (≤124 procedures) 
to 72.9% in the highest OTV group (>237 procedures); P<0.001. Patients in the TFA cohort 
were consistently older, were more likely to be female gender, have a previous history of 
CABG, have a previous history of MI, have diabetes, be hypertensive, and present with 
cardiogenic shock (all P<0.001) in all operator volume groups studied. Similar observations 
were recorded when center volume was studied (Table 2). Table 2 illustrates clinical and 
procedural demographics for the TRA and TFA groups by CTV. TRA utilization increased 
from 57.6% in the lowest CTV group (≤682 procedures) to 76.0% in the highest CTV group 
(>1633 procedures), P<0.001.  
 Crude 30-day mortality outcomes were significantly fewer in the TRA cohort 
compared to the TFA cohort across all volume groups studied both at the operator level 
(1.6% vs 3.9% in lowest operator volume group, 1.6% vs 4.9% in the highest operator 
volume group; P<0.001) and at the center volume level (1.2% vs 2.6% in the lowest center 
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volume group, 1.6% vs 5.1% in the highest center volume group; P<0.001). Similar 
observations were recorded for both in hospital MACE and major bleeding complications 
(Tables 1 and 2).   
 
Operator and center radial proportions and access site related outcomes 
 The relationship between ORP, CRP and access site related outcomes were studied. 
Tables 3 and 4 illustrate clinical and procedural demographics for the TRA and TFA groups 
stratified by radial proportion quartiles at the operator and center level respectively.  
 Crude 30-day mortality rates by access site (i.e., TRA versus TFA) were similar in the 
low ORP cohort defined as undertaking <25% of PCI procedures through the TRA route 
(TRA 2.2% and TFA 2.4%; P=0.561) but were significantly less in the TRA group compared 
to the TFA group in the remaining ORPgroups (mortality in highest ORP, TRA 1.7% and 
TFA 7.2%; P<0.001). In-hospital major bleeding and MACE was significantly lower in the 
TRA cohort compared to TFA cohort in all ORP groups studied, with this effect larger for 
MACE in high proportion radial operators (P<0.001) but not for bleeding (P=0.676). When 
crude 30-day mortality was studied according to CRP, similar findings were observed except 
that the effect of TRA vs TFA was not different by proportion groups for bleeding (P<0.001) 
(Table 4).  
Operator and centerradial volume and access site related outcomes 
 We subsequently studied the influence of ORV and CRV on outcomes. 
Supplementary Table 1 illustrates clinical and procedural demographics and clinical 
outcomes stratified by ORV group. Patients in the TFA cohort were consistently older, had a 
higher prevalence of comorbidities and were more likely to present with hemodynamic 
compromise in all operator radial volume groups studied. Similar observations were recorded 
when CRV was studied (Supplementary Table 2). 
 TRA was associated with lower crude 30-day mortality compared with TFA in all 
quartiles of operator and center radial volume studied (P<0.001).  
  
Adjusted analyses for operator/center volumes and proportions 
 Multiple logistic regression modeling for each experience measure independently 
indicated that experience increase was significantly associated with reductions in the TRA vs 
TFA odds-ratio (OR) for 30-day mortality, after adjustment for confounders. Supplementary 
Figure1illustrates and quantifies these associations for each of the experience measures.  
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 Multiple logistic regression modeling adjusting for other experience measures in 
addition to confounders showed an average odds reduction of 39%for 30-day mortality for 
TRA when compared with TFA (OR = 0.61, 95% CI 0.55 to 0.68, p<0.001), and indicated 
that only increasing OTV and ORP were significantly associated with reductions in the TRA 
vs TFA odds-ratio (OR) for 30-day mortality. Figure 4 illustrates and quantifies these 
associations for each of the experience measures. The magnitude of this risk reduction was 
modified by increases in OPV (OR reduction of 11% per 100 extra procedures, 95% CI 3-
19%) and by increases in ORV (OR reduction of 6% per 10%-point increase in radial 
proportion, 95% CI 1-11%) with no significant OR changes when varying by ORV, CTV, 
CRV and CRP. 
Sensitivity analyses for these regression models indicated that while some confounder 
interactions were significant additional adjustments did not materially affect the exposure 
parameters of interest; therefore, interactions between confounders were not included. Further, 
non-linear experience effects were investigated via restricted cubic splines and although some 
non-linearities were observed, these were often in low operator/center density spaces where 
model uncertainty is high, and made no practical difference to the principal observation that 
OTV and ORP are negatively associated with the TRA vs TFA mortality odds-ratio after 
adjustment for confounders and other experience measures. The exclusion of repeat 
admission during the study period to ensure independence between patients did not 
significantly alter the results of the primary analysis (compare Figure 4 with Supplementary 
Figure 2). 
Similarly restricting the analysis to PCI procedures undertakenin the non-cardiogenic 
shock setting, we demonstrate similar findings to the results for the whole cohort 
(Supplementary Figure 3). 
 
Discussion 
 Our analysis of around 150,000 PCI procedures undertaken nationally between 2012-
2013 suggests that there is significant variation in access site practice at both the individual 
operator and center level according to volume of procedures undertaken, with TRA used 
more commonly as operator/center volume increase. We report that TRA choice is 
independently associated with reduced 30-day mortality outcomes and that the magnitude of 
this lower mortality risk is not independently influenced by either increases in total 
procedural volume radial volume, or radial proportion at the center level. Finally, our study 
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suggests that higher total volume of procedures and higher proportion of cases undertaken 
radially at the operator level  are independently associated with a larger reduced odds of 
mortality, with an 11% reduction in the odds for 30-day mortality (compared to TFA use) for 
each 100 extra procedures performed per year, and an 8% reduction in the odds for 30-day 
mortality (compared to TFA use) for each 10% increase in the proportion of cases undertaken 
through the TRA approach.  
 Previous studies using data derived from randomized controlled trials14,15 and data 
derived from the Veterans Affairs (VA) Healthcare system16 have suggested a relationship 
between access site outcomes and procedural volumes. Analysis of 24,143 procedures 
undertaken in 49 VA sites between 2007-2010 suggested that the decreased rate of blood 
transfusions associated with TRA was only observed in high radial volume centers, defined 
as performing >50 TRA procedures a year.16 The RIVAL study reported that in the subgroup 
of high volume radial centers the primary outcome was reduced by TRA versus TFA, but not 
in intermediate- or low-volume radial centers and there was no significant interaction by 
individual operator radial volume.15 2In contrast, no significant differences in the primary 
bleeding endpoint were observed between the TRA and TFA arm by either operator radial 
volume, though this study suggests some evidence of a significant interaction at the center 
level. Subgroup analysis of the RIVAL study by center procedural volume illustrated a 
significant 8% reduction in the primary endpoint for overall PCI center volume a 12% 
reduction for radial center volume per 50 PCIs/year for median operator at center although 
this relationship was not observed for mortality outcomes. In a retrospective analysis derived 
from 8 centers in the UK, TRA utilization independently predicted decreased 30-day, 6-
month and 1-year mortality in patients undergoing PCI for NSTEMI indications although this 
benefit was only observed in high volume radial centers.25 Interestingly, in the recent 
MATRIX RCT, that demonstrated decreases in all cause mortality, MACE and major BARC 
3 or 5 bleeding rates in the TRA arm, with positive tests for trend across tertiles of the 
centers’ percentage of TRA for PCI for both co-primary outcomes and all-cause mortality, 
with a particularly pronounced benefit of TRA access in centers that did 80% or more radial 
percutaneous coronary interventions.26 
 Our analysis represents the first analysis to systematically study the relationship 
between TRA volume, total volume and TRA proportions at both the individual operator and 
center level in a nationwide setting where TRA is now the default access route3,27 in an 
unselected real world cohort of patients. We show that access site practice varies according to 
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volume of procedures undertaken at the operator and center level, with increased utilization 
of the TRA approach as operator and center volume increases. Furthermore it is interesting to 
note that we report that the size of the 30-day mortality risk decrease associated with TRA 
utilization is not independently influenced bycenter radial or total volume of procedures 
undertaken, but is independently influenced by operator total volume and radial proportion. 
Higher total volume of procedures and higher proportion of cases undertaken radially at the 
operator level are independently associated with a larger reduced odds of 30-day mortality. 
 Our analysis represents a broad spectrum of operators with varying access site 
practice and TRA experience. Previous analyses have been limited in that they have been 
undertaken in highly selected cohorts of patients in the RCT setting undergoing PCI for ACS 
indications where the highest risk patients such as those with hemodynamic instability where 
excluded and only experienced operators who undertook at least 50 TRA procedures in the 
previous year were included in the study.28 Similarly other studies analyzed data from US 
cohorts when TRA adoption was <10% at the time-points studied and the 5 high volume sites 
defined as >50 TRA procedures a year averaged 120 TRA procedures a year each which 
would place these centers in the lowest quartile (2-341 TRA procedures per year) in the 
current analysis.16 
 Our observation that the largest risk reduction associated with the TRA approach is 
amongst operators who utilize TRA in the highest proportion of their cases, and that this is 
not related to either total volume or radial volume at the center level once other covariates of 
patient clinical demographics and operator/center experience are adjusted for is of interest. 
Our previous work has suggested that the greatest mortality reduction associated with TRA 
adoption is derived from patients at highest baseline bleeding risk, who are often the most 
hemodynamically unstable, have adverse clinical characteristics such as the elderly, women, 
or are undergoing PCI for emergent indications whilst patients at low risk of bleeding 
complications gain little mortality benefit from adopting a TRA approach.5 The patients who 
are likely to gain most from adoption of TRA access site are also those in whom TRA is more 
challenging. High proportion TRA operators are likely to utilize the TRA approach in such 
patients who are at highest risk of bleeding complications who would derive the greatest 
mortality benefit from radial access site adoption, whereas low proportion TRA operators are 
more likely to use TRA approach in less challenging cases that would derive less/little 
mortality benefit from utilization of this access site. Radial volume will depend on both the 
total volume that an operator undertakes and the proportion of cases undertaken through the 
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TRA route; hence individuals may be high volume radial operators by virtue of undertaking a 
large volume of procedures but only undertaking a low proportion of such procedures 
through the TRA route. Such a ‘high volume’ radial operator may only undertake the least 
challenging cases that would derive a smaller mortality benefit of undertaking the procedure 
through the TRA approach. Previous literature has only considered radial/total volumes in 
isolation and not considered the proportion of cases undertaken through the TRA route when 
examining relationships between radial ‘experience’ and outcomes.4,14-16,25 The more recent 
MATRIX RCT showed a relationship between center TRA proportion and the co-primary 
outcome, with highest proportion radial centers having the greatest magnitude of benefit in 
the co-primary outcome, although data around operator proportion was not presented in this 
analysis.26 
 In the highest proportion radial operator and centre analysis, we have consistently 
observed that the cases undertaken through the femoral approach are much sicker, higher risk 
patients than those undertaken in the lowest proportion operators/centers. For example, at the 
operator level, in the highest proportion radial operator group cardiogenic shock represented 
9.2% of the femoral case mix in contrast to 2.5% in the lowest proportion radial operator 
group (P<0.001), with similar observations recorded at the centre level (7.5% vs 2.3%; 
P<0.001). In addition, similar findings were observed at both the centre and operator volume 
analyses. It has been previously argued that the more favorable radial outcomes reported at 
high proportion radial centers may relate to worse femoral outcomes in these centers at both 
the centre and operator level.29 Even after removal of the sickest patients such as those with 
cardiogenic shock in a sensitivity analysis, our findings that lower mortality associated with 
TRA adoption relates to both the total procedural volume and the proportion of procedures 
undertaken radially by operator, with operators undertaking the greatest proportion of their 
procedures radially having the largest relative reduction in mortality risk remain robust. 
Furthermore, data from the RIVAL has shown that whilst radial PCI centre volume was 
independently associated with a decrease in the composite primary outcome of death, 
myocardial infarction, stroke, non-CABG related major bleeding at 30 days(HR 0.88 95%CI 
0.80-0.97), femoral PCI centre volume was not (HR 1.03 95%CI 0.94-1.07) suggesting that 
mechanisms other than worse femoral outcomes in high volume radial centers, contribute to 
their better outcomes in cases undertaken transradially.2 
 Our study has a number of potential limitations. Whilst mortality tracking within 
England and Wales is robust, the cause of mortality is not available; and all other outcomes 
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and complications such as major bleeding events are self-reported and are not formally 
audited by BCIS, subjecting the data to reporting biases. Secondly, we were unable to 
account for crossover in access site because this data is not captured in the BCIS dataset. 
Finally, although we have attempted to correct for differences in baseline and procedural 
demographics observed between the TFA and TRA cohorts using a variety of statistical 
techniques the relationship between access site and favorable outcomes does not infer 
causality, and unmeasured confounders may contribute to the unfavorable outcomes observed 
in the TFA cohort. 
 In conclusion, in the largest analysis to date undertaken nationally to systematically 
study access site related outcomes and procedural volumes at both the operator and 
institutional level, we demonstrate that the lower mortality associated with TRA adoption 
relates to the proportion of procedures undertaken through the radial approach, and also the 
total volume of procedures, with operators undertaking the greatest proportion of their 
procedures radially having the largest relative reduction in mortality risk. We observe that the 
reduced mortality associated with TRA does not relate to either total volume or radial volume 
at the center level once other covariates of patient clinical demographics and operator 
experience are adjusted for.  
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Table 1: Clinical and procedural demographics stratified by access site and Operator Total Volumes. 
Volume of TFA only or TRA 
only procedures performed 
by operator (OTV) 
 
1. Lowest volume 
N=37,391 
(1-123 procedures) 
2. lower-mid volume 
 N=37,242 
(124-173 procedures) 
3. upper-mid volume 
 N=37,389 
(174-237 procedures) 
4. Highest volume 
N=37,143 
(238-658 procedures) 
 P-value for 
same effect size 
over groups 
  TRA TFA   TRA TFA   TRA TFA   TRA TFA    
All procedures, N  20,336 17,055   23,673 13,569   26,293 11,096   27,074 10,069    
                   
  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value   
Age  64.0 
(12.1) 
65.4 
(12.1) 
<0.001  64.0 
(11.9) 
66.0 
(12.2) 
<0.001  64.5 
(11.9) 
66.4 
(12.1) 
<0.001  64.9 
(12.0) 
67.2 
(12.3) 
<0.001  <0.001 
                   
  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value   
Sex -Male  15,560     
(76.5) 
12,261     
(71.9) 
<0.001  18,116     
(76.5) 
 9,573     
(70.6) 
<0.001  19,911     
(75.7) 
 7,786     
(70.2) 
<0.001  20,377     
(75.3) 
 7,055     
(70.1) 
<0.001  0.252 
 -Female  4,776     
(23.5) 
 4,794     
(28.1) 
 5,557     
(23.5) 
 3,996     
(29.4) 
 6,382     
(24.3) 
 3,310     
(29.8) 
 6,697     
(24.7) 
 3,014     
(29.9) 
 
Indication -Stable angina   6,484     
(31.9) 
 5,986     
(35.1) 
<0.001   7,436     
(31.4) 
 5,104     
(37.6) 
<0.001   8,481     
(32.3) 
 4,536     
(40.9) 
<0.001   9,269     
(34.2) 
 4,268     
(42.4) 
<0.001  <0.001 
 -UA/NSTEMI  7,950     
(39.1) 
 6,012     
(35.3) 
 9,007     
(38.0) 
 4,863     
(35.8) 
10,128     
(38.5) 
 3,876     
(34.9) 
10,700     
(39.5) 
 3,336     
(33.1) 
 
 -STEMI  5,902     
(29.0) 
 5,057     
(29.7) 
 7,230     
(30.5) 
 3,602     
(26.5) 
 7,684     
(29.2) 
 2,684     
(24.2) 
 7,105     
(26.2) 
 2,465     
(24.5) 
 
Shock     290     
( 1.4) 
   792     
( 4.7) 
<0.001     374     
( 1.6) 
   651     
( 4.8) 
<0.001     338     
( 1.3) 
   556     
( 5.0) 
<0.001     311     
( 1.2) 
   515     
( 5.2) 
<0.001  <0.001 
MI   4,249     
(22.1) 
 4,057     
(26.7) 
<0.001   4,996     
(22.6) 
 3,689     
(30.7) 
<0.001   6,019     
(24.0) 
 3,559     
(33.8) 
<0.001   6,583     
(25.4) 
 3,474     
(36.1) 
<0.001  <0.001 
CABG     887     
( 5.3) 
 1,952     
(13.8) 
<0.001     978     
( 5.8) 
 1,559     
(15.7) 
<0.001   1,080     
( 5.6) 
 1,529     
(17.6) 
<0.001   1,334     
( 5.8) 
 1,538     
(21.3) 
<0.001  <0.001 
Diabetes   3,925     
(19.9) 
 3,560     
(22.3) 
<0.001   4,396     
(19.1) 
 2,889     
(22.8) 
<0.001   4,816     
(19.1) 
 2,488     
(24.1) 
<0.001   5,036     
(20.0) 
 2,304     
(24.7) 
<0.001  <0.001 
Hypercholesterolemia   9,873     
(50.5) 
 8,120     
(49.8) 
0.246  12,515     
(54.5) 
 7,169     
(55.4) 
0.112  14,701     
(58.2) 
 6,403     
(60.7) 
<0.001  14,230     
(56.2) 
 5,579     
(59.9) 
<0.001  <0.001 
Hypertension  10,138     
(51.8) 
 8,833     
(54.2) 
<0.001  12,286     
(53.5) 
 7,393     
(57.1) 
<0.001  13,663     
(54.1) 
 6,374     
(60.4) 
<0.001  14,464     
(57.1) 
 6,010     
(64.6) 
<0.001  <0.001 
Renal -Normal  19,113 
(98.0) 
15,483 
(96.2) 
<0.001  22,219      
(98.4) 
12,272      
(95.7) 
<0.001  24,788      
(98.5) 
10,246      
(95.9) 
<0.001  25,537      
(98.4) 
 8,955      
(95.2) 
<0.001  <0.001 
 -High creatinine 258 
(1.3) 
374 
(2.3) 
   243      
( 1.1) 
   324      
( 2.5) 
   291      
( 1.2) 
   253      
( 2.4) 
   301      
( 1.2) 
   235      
( 2.5) 
 
 -Dialysis 123 
(0.6) 
243 
(1.5) 
   122      
( 0.5) 
   223      
( 1.7) 
    96      
( 0.4) 
   183      
( 1.7) 
   112      
( 0.4) 
   212      
( 2.3) 
 
Smoking  11,388     
(60.9) 
 9,065     
(61.2) 
0.692  13,746     
(63.5) 
 7,114     
(60.6) 
<0.001  15,764     
(64.7) 
 6,131     
(61.6) 
<0.001  16,394     
(65.2) 
 5,453     
(60.4) 
<0.001  <0.001 
Glycoprotein IIb/IIIa   4,373      3,398     0.014   4,701      2,151     <0.001   4,743      1,622     <0.001   4,209      1,281     <0.001  <0.001 
21 
 
inhibitors (22.2) (21.1) (20.8) (17.4) (18.8) (15.3) (15.7) (13.0) 
Intra-aortic balloon pump     141     
( 0.7) 
   440     
( 2.7) 
<0.001     150     
( 0.7) 
   426     
( 3.4) 
<0.001     163     
( 0.6) 
   376     
( 3.6) 
<0.001     183     
( 0.7) 
   325     
( 3.3) 
<0.001  0.027 
Cardiopulmonary support      15     
( 0.1) 
    41     
( 0.3) 
<0.001       8      
(<0.1) 
    41     
( 0.3) 
<0.001      22     
( 0.1) 
    23     
( 0.2) 
0.003      19     
( 0.1) 
    18     
( 0.2) 
0.005  0.018 
Inotropes     127     
( 0.6) 
   267     
( 1.6) 
<0.001     116     
( 0.5) 
   218     
( 1.8) 
<0.001     111     
( 0.4) 
   161     
( 1.5) 
<0.001     144     
( 0.5) 
   163     
( 1.6) 
<0.001  0.175 
Ventilated     187     
( 1.0) 
   578     
( 3.8) 
<0.001     210     
( 1.0) 
   448     
( 4.0) 
<0.001     238     
( 1.0) 
   373     
( 3.7) 
<0.001     256     
( 1.0) 
   344     
( 3.8) 
<0.001  0.975 
Stents -BMS only   2,770     
(14.2) 
 2,119     
(13.1) 
<0.001   3,118     
(13.9) 
 1,571     
(12.5) 
<0.001   3,315     
(12.9) 
 1,267     
(11.7) 
<0.001   2,422     
( 9.1) 
   963     
(10.0) 
<0.001  <0.001 
 -DES only 15,042     
(77.2) 
12,439     
(77.2) 
17,043     
(76.0) 
 9,547     
(76.0) 
19,751     
(77.0) 
 8,141     
(75.2) 
20,758     
(77.8) 
 7,336     
(75.9) 
 
 -BMS and DES    429     
( 2.2) 
   289     
( 1.8) 
   565     
( 2.5) 
   323     
( 2.6) 
   604     
( 2.4) 
   233     
( 2.2) 
   552     
( 2.1) 
   170     
( 1.8) 
 
LVEF -Good (>50%)   6,425     
(71.1) 
 4,982     
(68.6) 
<0.001   7,999     
(72.9) 
 4,042     
(65.9) 
<0.001   9,938     
(73.3) 
 3,884     
(68.2) 
<0.001  10,599     
(71.1) 
 4,340     
(69.9) 
<0.001  <0.001 
 -Fair (30-50%)  2,113     
(23.4) 
 1,731     
(23.8) 
 2,409     
(22.0) 
 1,630     
(26.6) 
 2,958     
(21.8) 
 1,342     
(23.6) 
 3,446     
(23.1) 
 1,373     
(22.1) 
 
 -Poor (<30%)    494     
( 5.5) 
   545     
( 7.5) 
   558     
( 5.1) 
   465     
( 7.6) 
   664     
( 4.9) 
   469     
( 8.2) 
   854     
( 5.7) 
   492     
( 7.9) 
 
30-day mortality     317     
( 1.6) 
   641     
( 3.9) 
<0.001     389     
( 1.7) 
   569     
( 4.3) 
<0.001     411     
( 1.6) 
   447     
( 4.1) 
<0.001     418     
( 1.6) 
   483     
( 4.9) 
<0.001  0.025 
Bleeding      65     
( 0.3) 
   223     
( 1.3) 
<0.001      92     
( 0.4) 
   168     
( 1.3) 
<0.001      93     
( 0.4) 
   192     
( 1.8) 
<0.001      84     
( 0.3) 
   136     
( 1.4) 
<0.001  0.110 
MACE     284     
( 1.4) 
   524     
( 3.1) 
<0.001     347     
( 1.5) 
   477     
( 3.6) 
<0.001     367     
( 1.4) 
   368     
( 3.4) 
<0.001     334     
( 1.2) 
   430     
( 4.3) 
<0.001  <0.001 
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Table 2: Clinical and procedural demographics stratified by access site and Centre Total Volume. 
Volume of TFA only or TRA 
only procedures performed 
yearly by center (CTV) 
 
1. Lowest volume 
N=37,425 
(71-682 procedures) 
2. lower-mid volume 
N=37,474 
(717-1296 procedures) 
3. upper-mid volume 
N=37,306 
(1301-1603 procedures) 
4. Highest volume 
N=36,960 
(1633-2944 procedures) 
 P-value for 
same effect size 
over groups 
  TRA TFA   TRA TFA   TRA TFA   TRA TFA    
All procedures, N    21,581 15,844   23,066 14,408   24,645 12,661   28,084 8,876    
                   
  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value   
Age  65.1 
(11.8) 
66.5 
(11.8) 
<0.001  64.3 
(12.1) 
66.2 
(12.3) 
<0.001  63.9 
(12.0) 
65.5 
(12.4) 
<0.001  64.2 
(12.0) 
66.2 
(12.4) 
<0.001  0.020 
                   
  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value   
Sex -Male  16,357      
(75.8) 
11,278      
(71.2) 
<0.001  17,572      
(76.2) 
10,298      
(71.5) 
<0.001  18,809      
(76.3) 
 8,943      
(70.6) 
<0.001  21,226      
(75.6) 
 6,156      
(69.4) 
<0.001  0.091 
 -Female  5,224      
(24.2) 
 4,566      
(28.8) 
 5,494      
(23.8) 
 4,110      
(28.5) 
 5,836      
(23.7) 
 3,718      
(29.4) 
 6,858      
(24.4) 
 2,720      
(30.6) 
 
Indication -Stable angina   8,191      
(38.0) 
 6,691      
(42.2) 
<0.001   6,456      
(28.0) 
 5,178      
(35.9) 
<0.001   7,619      
(30.9) 
 4,467      
(35.3) 
<0.001   9,404      
(33.5) 
 3,558      
(40.1) 
<0.001  <0.001 
 -UA/NSTEMI 10,565      
(49.0) 
 6,782      
(42.8) 
 8,560      
(37.1) 
 4,803      
(33.3) 
 8,398      
(34.1) 
 3,669      
(29.0) 
10,262      
(36.5) 
 2,833      
(31.9) 
 
 -STEMI  2,825      
(13.1) 
 2,371      
(15.0) 
 8,050      
(34.9) 
 4,427      
(30.7) 
 8,628      
(35.0) 
 4,525      
(35.7) 
 8,418      
(30.0) 
 2,485      
(28.0) 
 
Shock     240      
( 1.1) 
   442      
( 2.8) 
<0.001     446      
( 2.0) 
   886      
( 6.2) 
<0.001     354      
( 1.4) 
   677      
( 5.4) 
<0.001     273      
( 1.0) 
   509      
( 5.7) 
<0.001  <0.001 
Myocardial infarction   5,571      
(26.8) 
 4,249      
(31.1) 
<0.001   4,701      
(22.5) 
 3,907      
(29.5) 
<0.001   5,250      
(22.6) 
 3,707      
(31.1) 
<0.001   6,325      
(23.0) 
 2,916      
(34.2) 
<0.001  <0.001 
Coronary artery bypass graft   1,018      
( 5.3) 
 1,947      
(14.7) 
<0.001     757      
( 4.6) 
 1,684      
(14.8) 
<0.001   1,040      
( 8.2) 
 1,357      
(19.8) 
<0.001   1,464      
( 5.4) 
 1,590      
(18.6) 
<0.001  <0.001 
Diabetes   4,337      
(20.6) 
 3,247      
(22.3) 
<0.001   4,202      
(18.7) 
 3,231      
(23.5) 
<0.001   4,438      
(18.4) 
 2,690      
(21.8) 
<0.001   5,196      
(20.3) 
 2,073      
(27.0) 
<0.001  <0.001 
Hypercholesterolemia  11,787      
(56.5) 
 8,343      
(54.7) 
<0.001  12,088      
(54.5) 
 7,603      
(55.4) 
0.086  14,859      
(61.3) 
 7,508      
(61.3) 
0.994  12,585      
(48.8) 
 3,817      
(48.5) 
0.652  0.004 
Hypertension  11,613      
(55.6) 
 8,508      
(55.8) 
0.780  12,254      
(55.2) 
 8,411      
(61.3) 
<0.001  13,046      
(53.8) 
 7,106      
(58.0) 
<0.001  13,638      
(52.9) 
 4,585      
(58.2) 
<0.001  <0.001 
Renal -Normal  20,395      
(98.0) 
14,375      
(95.9) 
<0.001  21,396      
(98.1) 
13,015      
(95.5) 
<0.001  23,629      
(98.5) 
11,587      
(96.0) 
<0.001  26,237      
(98.6) 
 7,979      
(96.0) 
<0.001  <0.001 
 -High creatinine    296      
( 1.4) 
   430      
( 2.9) 
   304      
( 1.4) 
   326      
( 2.4) 
   235      
( 1.0) 
   258      
( 2.1) 
   258      
( 1.0) 
   172      
( 2.1) 
 
 -Dialysis    111      
( 0.5) 
   183      
( 1.2) 
   112      
( 0.5) 
   292      
( 2.1) 
   125      
( 0.5) 
   228      
( 1.9) 
   105      
( 0.4) 
   158      
( 1.9) 
 
Smoking  12,475      
(62.6) 
 8,527      
(62.2) 
0.482  13,694      
(66.2) 
 7,941      
(63.4) 
<0.001  15,254      
(64.9) 
 6,700      
(57.7) 
<0.001  15,869      
(61.7) 
 4,595      
(59.5) 
<0.001  <0.001 
Glycoprotein IIb/IIIa   3,445       2,423      0.904   5,214       2,496      <0.001   4,758       2,056      <0.001   4,609       1,477      0.400  <0.001 
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inhibitors (16.0) (16.1) (23.5) (18.0) (20.5) (18.1) (16.7) (17.1) 
Intra-aortic balloon pump      95      
( 0.4) 
   273      
( 1.8) 
<0.001     234      
( 1.0) 
   514      
( 3.6) 
<0.001     187      
( 0.8) 
   493      
( 4.5) 
<0.001     121      
( 0.4) 
   287      
( 3.3) 
<0.001  <0.001 
Cardiopulmonary support      20      
( 0.1) 
    47      
( 0.3) 
<0.001      20      
( 0.1) 
    44      
( 0.3) 
<0.001       7      
( 0.0) 
    15      
( 0.1) 
<0.001      17      
( 0.1) 
    17      
( 0.2) 
<0.001  0.926 
Inotropes      94      
( 0.4) 
   190      
( 1.2) 
<0.001     190      
( 0.8) 
   289      
( 2.0) 
<0.001     113      
( 0.5) 
   153      
( 1.4) 
<0.001     101      
( 0.4) 
   177      
( 2.0) 
<0.001  <0.001 
Ventilated     222      
( 1.1) 
   340      
( 2.4) 
<0.001     228      
( 1.1) 
   570      
( 4.2) 
<0.001     160      
( 0.8) 
   406      
( 4.4) 
<0.001     281      
( 1.0) 
   427      
( 5.0) 
<0.001  <0.001 
Stents -BMS only   2,859      
(13.6) 
 1,682      
(11.3) 
<0.001   3,148      
(14.6) 
 1,683      
(12.7) 
<0.001   2,964      
(12.4) 
 1,568      
(12.8) 
<0.001   2,654      
( 9.6) 
   987      
(11.3) 
<0.001  <0.001 
 -DES only 15,907      
(75.8) 
11,697      
(78.3) 
16,502      
(76.4) 
10,080      
(75.9) 
18,352      
(76.9) 
 9,111      
(74.5) 
21,833      
(78.6) 
 6,575      
(75.4) 
 
 -BMS and DES    748      
( 3.6) 
   331      
( 2.2) 
   401      
( 1.9) 
   255      
( 1.9) 
   546      
( 2.3) 
   276      
( 2.3) 
   455      
( 1.6) 
   153      
( 1.8) 
 
LVEF -Good (>50%)   9,198      
(76.1) 
 6,590      
(72.1) 
<0.001   7,176      
(67.8) 
 3,262      
(62.7) 
<0.001   8,606      
(72.4) 
 4,423      
(69.3) 
<0.001   9,981      
(71.8) 
 2,973      
(65.0) 
<0.001  <0.001 
 -Fair (30-50%)  2,335      
(19.3) 
 2,062      
(22.6) 
 2,701      
(25.5) 
 1,403      
(27.0) 
 2,708      
(22.8) 
 1,502      
(23.5) 
 3,182      
(22.9) 
 1,109      
(24.2) 
 
 -Poor (<30%)    549      
( 4.5) 
   487      
( 5.3) 
   709      
( 6.7) 
   534      
(10.3) 
   574      
( 4.8) 
   458      
( 7.2) 
   738      
( 5.3) 
   492      
(10.8) 
 
30-day mortality     259      
( 1.2) 
   399      
( 2.6) 
<0.001     449      
( 2.0) 
   657      
( 4.7) 
<0.001     392      
( 1.6) 
   639      
( 5.3) 
<0.001     435      
( 1.6) 
   445      
( 5.1) 
<0.001  <0.001 
Bleeding      78      
( 0.4) 
   186      
( 1.2) 
<0.001      93      
( 0.4) 
   267      
( 1.9) 
<0.001     104      
( 0.4) 
   172      
( 1.4) 
<0.001      59      
( 0.2) 
    94      
( 1.1) 
<0.001  0.048 
MACE     235      
( 1.1) 
   318      
( 2.0) 
<0.001     366      
( 1.6) 
   552      
( 3.9) 
<0.001     372      
( 1.6) 
   584      
( 4.9) 
<0.001     359      
( 1.3) 
   345      
( 3.9) 
<0.001  <0.001 
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Table 3:Clinical and procedural demographics stratified by access site and Operator Radial Volume. 
Proportion of procedures 
performed via TRA 
yearly, by operator (ORP) 
 
1. Lowest proportion 
 N=25,754 
(0-25% TRA procedures) 
2. lower-mid proportion 
N=8,956 
(25-50% TRA procedures) 
3. upper-mid proportion 
N=34,491 
(50-75% TRA procedures) 
4. Highest proportion 
N=79,964 
(75-100% TRA procedures) 
 P-value for same 
effect size over 
groups 
  TRA TFA   TRA TFA   TRA TFA   TRA TFA    
All procedures, N  2,008 23,746   3,415 5,541   22,843 11,648   69,110 10,854    
                   
  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value   
Age  64.6 
(12.1) 
65.6 
(12.0) 
<0.001  63.5 
(11.8) 
65.4 
(12.4) 
<0.001  64.3 
(12.1) 
66.7 
(12.2) 
<0.001  64.4 
(11.9) 
67.1 
(12.3) 
<0.001  <0.001 
                   
  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value   
Sex -Male   1,583      
(78.8) 
17,594      
(74.1) 
<0.001   2,757      
(80.7) 
 4,011      
(72.4) 
<0.001  17,564      
(76.9) 
 7,936      
(68.1) 
<0.001  52,060      
(75.3) 
 7,134      
(65.7) 
<0.001  0.012 
 -Female    425      
(21.2) 
 6,152      
(25.9) 
   658      
(19.3) 
 1,530      
(27.6) 
 5,279      
(23.1) 
 3,712      
(31.9) 
17,050      
(24.7) 
 3,720      
(34.3) 
 
Indication -Stable angina     859      
(42.8) 
 9,270      
(39.0) 
<0.001   1,350      
(39.5) 
 2,184      
(39.4) 
<0.001   7,662      
(33.5) 
 4,433      
(38.1) 
<0.001  21,799      
(31.5) 
 4,007      
(36.9) 
<0.001  <0.001 
 -UA/NSTEMI    837      
(41.7) 
 8,314      
(35.0) 
 1,210      
(35.4) 
 1,655      
(29.9) 
 8,714      
(38.1) 
 4,179      
(35.9) 
27,024      
(39.1) 
 3,939      
(36.3) 
 
 -STEMI    312      
(15.5) 
 6,162      
(25.9) 
   855      
(25.0) 
 1,702      
(30.7) 
 6,467      
(28.3) 
 3,036      
(26.1) 
20,287      
(29.4) 
 2,908      
(26.8) 
 
Shock      21      
( 1.1) 
   585      
( 2.5) 
<0.001      38      
( 1.1) 
   244      
( 4.4) 
<0.001     233      
( 1.0) 
   692      
( 6.0) 
<0.001   1,021      
( 1.5) 
   993      
( 9.2) 
<0.001  <0.001 
Myocardial infarction     544      
(28.0) 
 5,427      
(25.3) 
0.008     759      
(23.1) 
 1,536      
(29.2) 
<0.001   4,983      
(23.6) 
 3,806      
(36.1) 
<0.001  15,561      
(23.6) 
 4,010      
(39.9) 
<0.001  <0.001 
Coronary artery bypass graft     117      
( 7.5) 
 1,997      
(11.1) 
<0.001     127      
( 5.0) 
   654      
(15.4) 
<0.001     986      
( 5.3) 
 1,937      
(20.4) 
<0.001   3,049      
( 5.7) 
 1,990      
(24.1) 
<0.001  <0.001 
Diabetes     467      
(24.2) 
 4,445      
(20.4) 
<0.001     746      
(23.1) 
 1,300      
(24.9) 
0.06   4,546      
(20.8) 
 2,906      
(26.2) 
<0.001  12,414      
(18.8) 
 2,590      
(25.5) 
<0.001  <0.001 
Hypercholesterolemia   1,192      
(61.2) 
11,888      
(52.6) 
<0.001   1,894      
(58.5) 
 2,965      
(56.3) 
0.055  11,621      
(53.5) 
 6,387      
(58.0) 
<0.001  36,612      
(55.3) 
 6,031      
(59.1) 
<0.001  <0.001 
Hypertension   1,199      
(61.6) 
12,448      
(55.1) 
<0.001   1,941      
(59.9) 
 3,144      
(59.7) 
0.876  11,992      
(55.2) 
 6,814      
(61.8) 
<0.001  35,419      
(53.5) 
 6,204      
(60.8) 
<0.001  <0.001 
Renal -Normal   1,883      
(97.5) 
21,612      
(96.9) 
0.298   3,208      
(97.6) 
 5,090      
(95.7) 
<0.001  21,680      
(98.0) 
10,564      
(94.5) 
<0.001  64,886      
(98.5) 
 9,690      
(94.9) 
<0.001  <0.001 
 -High creatinine     29      
( 1.5) 
   449      
( 2.0) 
    44      
( 1.3) 
   121      
( 2.3) 
   297      
( 1.3) 
   340      
( 3.0) 
   723      
( 1.1) 
   276      
( 2.7) 
 
 -Dialysis     20      
( 1.0) 
   233      
( 1.0) 
    36      
( 1.1) 
   109      
( 2.0) 
   143      
( 0.6) 
   271      
( 2.4) 
   254      
( 0.4) 
   248      
( 2.4) 
 
Smoking   1,193      
(65.8) 
12,645      
(61.2) 
<0.001   1,930      
(62.4) 
 2,907      
(58.9) 
0.002  13,009      
(62.7) 
 6,166      
(59.9) 
<0.001  41,160      
(64.1) 
 6,045      
(62.6) 
0.003  0.067 
Glycoprotein IIb/IIIa     187       3,407      <0.001     478       1,085      <0.001   4,484       2,107      0.002  12,877       1,853      <0.001  <0.001 
25 
 
inhibitors ( 9.6) (15.5) (14.6) (20.4) (20.4) (19.0) (19.1) (17.7) 
Intra-aortic balloon pump       6      
( 0.3) 
   425      
( 1.9) 
<0.001      18      
( 0.6) 
   144      
( 2.8) 
<0.001     159      
( 0.7) 
   403      
( 3.6) 
<0.001     454      
( 0.7) 
   595      
( 5.7) 
<0.001  <0.001 
Cardiopulmonary support       2      
( 0.1) 
    39      
( 0.2) 
0.663       1      
(<0.1) 
    13      
( 0.2) 
0.036       6      
(<0.1) 
    23      
( 0.2) 
<0.001      55      
( 0.1) 
    48      
( 0.5) 
<0.001  0.469 
Inotropes      10      
( 0.5) 
   195      
( 0.9) 
0.134       4      
( 0.1) 
    61      
( 1.2) 
<0.001      89      
( 0.4) 
   197      
( 1.8) 
<0.001     395      
( 0.6) 
   356      
( 3.4) 
<0.001  0.002 
Ventilated      15      
( 0.8) 
   398      
( 1.9) 
<0.001      14      
( 0.5) 
   143      
( 2.9) 
<0.001     176      
( 0.9) 
   564      
( 5.5) 
<0.001     686      
( 1.1) 
   638      
( 6.6) 
<0.001  0.013 
Stents -BMS only     238      
(12.3) 
 2,392      
(10.7) 
0.176     458      
(13.7) 
   728      
(13.4) 
0.023   2,638      
(12.0) 
 1,415      
(12.7) 
<0.001   8,291      
(12.4) 
 1,385      
(13.4) 
<0.001  <0.001 
 -DES only  1,524      
(79.0) 
17,880      
(80.3) 
 2,592      
(77.8) 
 4,118      
(76.1) 
17,269      
(78.4) 
 8,129      
(73.1) 
51,209      
(76.5) 
 7,336      
(70.8) 
 
 -BMS and DES     30      
( 1.6) 
   390      
( 1.8) 
    57      
( 1.7) 
   115      
( 2.1) 
   401      
( 1.8) 
   270      
( 2.4) 
 1,662      
( 2.5) 
   240      
( 2.3) 
 
LVEF -Good (>50%)     683      
(76.7) 
 8,179      
(75.1) 
0.074   1,213      
(78.9) 
 1,800      
(71.5) 
<0.001   7,542      
(71.8) 
 3,598      
(62.8) 
<0.001  25,523      
(71.8) 
 3,671      
(59.7) 
<0.001  <0.001 
 -Fair (30-50%)    159      
(17.8) 
 2,235      
(20.5) 
   261      
(17.0) 
   565      
(22.4) 
 2,343      
(22.3) 
 1,539      
(26.9) 
 8,163      
(23.0) 
 1,737      
(28.2) 
 
 -Poor (<30%)     49      
( 5.5) 
   484      
( 4.4) 
    63      
( 4.1) 
   152      
( 6.0) 
   612      
( 5.8) 
   591      
(10.3) 
 1,846      
( 5.2) 
   744      
(12.1) 
 
30-day mortality      42      
( 2.2) 
   550      
( 2.4) 
0.561      44      
( 1.4) 
   191      
( 3.6) 
<0.001     322      
( 1.5) 
   635      
( 5.6) 
<0.001   1,127      
( 1.7) 
   764      
( 7.2) 
<0.001  <0.001 
Bleeding       6      
( 0.3) 
   291      
( 1.3) 
<0.001       6      
( 0.2) 
    48      
( 0.9) 
<0.001      85      
( 0.4) 
   186      
( 1.6) 
<0.001     237      
( 0.4) 
   194      
( 1.8) 
<0.001  0.676 
MACE      30      
( 1.5) 
   516      
( 2.2) 
0.052      38      
( 1.1) 
   195      
( 3.6) 
<0.001     314      
( 1.4) 
   508      
( 4.4) 
<0.001     950      
( 1.4) 
   580      
( 5.4) 
<0.001  <0.001 
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Table 4: Clinical and procedural demographics stratified by access site and Centre Radial Proportion. 
Proportion of procedures 
performed via TRA 
yearly, by center (CRP) 
 
1. Lowest proportion 
N=12,846 
(0-25% TRA procedures) 
2. lower-mid proportion 
N=19,478 
(25-50% TRA procedures) 
3. upper-mid proportion 
N=53,039 
(50-75% TRA procedures) 
4. Highest proportion 
N=63,802 
(75-100% TRA procedures) 
 P-value for same 
effect size over 
groups 
  TRA TFA   TRA TFA   TRA TFA   TRA TFA    
All procedures, N  1,864 10,982   7,119 12,359   35,289 17,750   53,104 10,698    
                   
  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value  Mean 
(SD) 
Mean 
(SD) 
p-value   
Age  65.8 
(11.6) 
66.6 
(12.0) 
0.004  64.4 
(12.1) 
65.7 
(12.2) 
<0.001  64.2 
(12.0) 
65.9 
(12.3) 
<0.001  64.4 
(11.9) 
66.6 
(12.2) 
<0.001  <0.001 
                   
  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value  N  
(%) 
N  
(%) 
p-value   
Sex -Male   1,485      
(79.7) 
 8,046      
(73.3) 
<0.001   5,504      
(77.3) 
 9,021      
(73.0) 
<0.001  27,155      
(77.0) 
12,442      
(70.1) 
<0.001  39,820      
(75.0) 
 7,166      
(67.0) 
<0.001  0.002 
 -Female    379      
(20.3) 
 2,936      
(26.7) 
 1,615      
(22.7) 
 3,338      
(27.0) 
 8,134      
(23.0) 
 5,308      
(29.9) 
13,284      
(25.0) 
 3,532      
(33.0) 
 
Indication -Stable angina     878      
(47.1) 
 4,802      
(43.7) 
0.024   2,475      
(34.8) 
 4,436      
(35.9) 
<0.001  11,825      
(33.5) 
 6,718      
(37.8) 
<0.001  16,492      
(31.1) 
 3,938      
(36.8) 
<0.001  <0.001 
 -UA/NSTEMI    685      
(36.7) 
 4,260      
(38.8) 
 2,770      
(38.9) 
 4,238      
(34.3) 
12,930      
(36.6) 
 5,654      
(31.9) 
21,400      
(40.3) 
 3,935      
(36.8) 
 
 - STEMI    301      
(16.1) 
 1,920      
(17.5) 
 1,874      
(26.3) 
 3,685      
(29.8) 
10,534      
(29.9) 
 5,378      
(30.3) 
15,212      
(28.6) 
 2,825      
(26.4) 
 
Shock      22      
( 1.2) 
   244      
( 2.3) 
0.004     106      
( 1.5) 
   490      
( 4.0) 
<0.001     456      
( 1.3) 
   977      
( 5.5) 
<0.001     729      
( 1.4) 
   803      
( 7.5) 
<0.001  <0.001 
Myocardial infarction     518      
(28.8) 
 2,646      
(28.8) 
0.998   1,602      
(23.9) 
 3,200      
(27.0) 
<0.001   7,650      
(23.8) 
 5,152      
(32.0) 
<0.001  12,077      
(23.4) 
 3,781      
(37.0) 
<0.001  <0.001 
Coronary artery bypass 
graft 
     87      
( 5.9) 
 1,130      
(12.9) 
<0.001     342      
( 6.8) 
 1,188      
(14.5) 
<0.001   1,561      
( 5.7) 
 2,500      
(17.3) 
<0.001   2,289      
( 5.5) 
 1,760      
(20.5) 
<0.001  <0.001 
Diabetes     466      
(25.7) 
 2,313      
(23.1) 
0.019   1,392      
(20.1) 
 2,535      
(21.2) 
0.062   6,703      
(20.9) 
 3,901      
(24.5) 
<0.001   9,612      
(18.4) 
 2,492      
(23.9) 
<0.001  <0.001 
Hypercholesterolemia   1,163      
(63.0) 
 6,159      
(57.4) 
<0.001   3,990      
(58.0) 
 6,493      
(55.2) 
<0.001  17,895      
(54.3) 
 8,782      
(53.7) 
0.176  28,271      
(54.9) 
 5,837      
(57.0) 
<0.001  <0.001 
Hypertension   1,224      
(66.3) 
 6,471      
(60.3) 
<0.001   3,999      
(58.2) 
 6,708      
(57.0) 
0.126  17,881      
(54.3) 
 9,333      
(57.1) 
<0.001  27,447      
(53.3) 
 6,098      
(59.6) 
<0.001  <0.001 
Renal -Normal   1,728      
(96.5) 
 9,973      
(96.6) 
0.834   6,702      
(97.5) 
11,247      
(95.6) 
<0.001  32,579      
(98.2) 
15,992      
(95.7) 
<0.001  50,648      
(98.6) 
 9,744      
(95.5) 
<0.001  <0.001 
 -High creatinine     44      
( 2.5) 
   231      
( 2.2) 
   122      
( 1.8) 
   324      
( 2.8) 
   398      
( 1.2) 
   367      
( 2.2) 
   529      
( 1.0) 
   264      
( 2.6) 
 
 -Dialysis     19      
( 1.1) 
   115      
( 1.1) 
    47      
( 0.7) 
   192      
( 1.6) 
   191      
( 0.6) 
   359      
( 2.1) 
   196      
( 0.4) 
   195      
( 1.9) 
 
Smoking   1,113      
(67.0) 
 6,059      
(65.0) 
0.132   3,915      
(59.9) 
 6,074      
(54.5) 
<0.001  19,815      
(63.2) 
 9,478      
(62.3) 
0.061  32,449      
(64.5) 
 6,152      
(62.3) 
<0.001  <0.001 
Glycoprotein IIb/IIIa     149       1,063      0.004   1,121       2,041      0.066   7,074       3,549      0.209   9,682       1,799      0.002  <0.001 
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inhibitors ( 8.1) (10.3) (16.3) (17.4) (21.2) (21.6) (18.5) (17.2) 
Intra-aortic balloon pump       4      
( 0.2) 
   190      
( 1.8) 
<0.001      70      
( 1.1) 
   328      
( 2.9) 
<0.001     247      
( 0.7) 
   564      
( 3.4) 
<0.001     316      
( 0.6) 
   485      
( 4.6) 
<0.001  <0.001 
Circulatory support       1      
( 0.1) 
    22      
( 0.2) 
0.274       1      
(<0.1) 
    26      
( 0.2) 
<0.001      19      
( 0.1) 
    25      
( 0.2) 
0.002      43      
( 0.1) 
    50      
( 0.5) 
<0.001  0.092 
Inotropes       3      
( 0.2) 
    82      
( 0.8) 
0.006      33      
( 0.5) 
   183      
( 1.6) 
<0.001     114      
( 0.3) 
   237      
( 1.4) 
<0.001     348      
( 0.7) 
   307      
( 2.9) 
<0.001  0.497 
Ventilated      14      
( 0.8) 
   221      
( 2.2) 
<0.001      63      
( 1.1) 
   315      
( 3.1) 
<0.001     274      
( 0.9) 
   671      
( 4.4) 
<0.001     540      
( 1.1) 
   536      
( 5.4) 
<0.001  <0.001 
Stents -BMS only     211      
(11.8) 
 1,141      
(11.3) 
0.006     796      
(11.8) 
 1,385      
(11.7) 
0.21   4,296      
(12.6) 
 2,162      
(12.8) 
<0.001   6,322      
(12.2) 
 1,232      
(11.9) 
<0.001  <0.001 
 -DES only  1,438      
(80.4) 
 7,998      
(79.2) 
 5,306      
(78.6) 
 9,261      
(78.4) 
26,387      
(77.7) 
12,702      
(75.3) 
39,463      
(76.3) 
 7,502      
(72.2) 
 
 -BMS and DES     38      
( 2.1) 
   162      
( 1.6) 
   177      
( 2.6) 
   268      
( 2.3) 
   613      
( 1.8) 
   332      
( 2.0) 
 1,322      
( 2.6) 
   253      
( 2.4) 
 
LVEF -Good (>50%)     590      
(76.1) 
 3,938      
(75.5) 
0.937   2,273      
(81.2) 
 3,861      
(75.8) 
<0.001  13,159      
(73.5) 
 5,767      
(65.5) 
<0.001  18,939      
(70.2) 
 3,682      
(59.6) 
<0.001  <0.001 
 -Fair (30-50%)    147      
(19.0) 
 1,016      
(19.5) 
   401      
(14.3) 
   998      
(19.6) 
 3,855      
(21.5) 
 2,290      
(26.0) 
 6,523      
(24.2) 
 1,772      
(28.7) 
 
 -Poor (<30%)     38      
( 4.9) 
   259      
( 5.0) 
   125      
( 4.5) 
   235      
( 4.6) 
   888      
( 5.0) 
   754      
( 8.6) 
 1,519      
( 5.6) 
   723      
(11.7) 
 
30-day mortality      33      
( 1.9) 
   229      
( 2.2) 
0.484     112      
( 1.6) 
   449      
( 3.8) 
<0.001     541      
( 1.6) 
   818      
( 4.7) 
<0.001     849      
( 1.6) 
   644      
( 6.1) 
<0.001  <0.001 
Bleeding      18      
( 1.0) 
   182      
( 1.7) 
0.034      29      
( 0.4) 
   135      
( 1.1) 
<0.001     101      
( 0.3) 
   198      
( 1.1) 
<0.001     186      
( 0.4) 
   204      
( 1.9) 
<0.001  <0.001 
MACE      29      
( 1.6) 
   229      
( 2.1) 
0.158     105      
( 1.5) 
   403      
( 3.4) 
<0.001     471      
( 1.4) 
   637      
( 3.7) 
<0.001     727      
( 1.4) 
   530      
( 5.0) 
<0.001  <0.001 
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Figure 1: Flow chart of cohort selection, data processing and analysis. 
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Figure 2:Yearly Radial Proportion against Total Volume, by operator (ORP vs OTV) and by 
centre (CRP vs CTV). 
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Figure 3:Procedures according to access site by year quarter 
31 
 
 
32 
 
 
Figure 4: Relationship between access site and 30-day mortality against different experience 
variables, after adjustment for clinical confounders and other experience 
variables.
 
 
 
